Novo Nordisk (NVO) said in a statement on Monday that it would halt its collaboration with Hims & Hers Health (HIMS) and that direct access to Wegovy would no longer be available to Hims & Hers Health via the NovoCare Pharmacy. The two companies had announced a collaboration in April for Hims & Hers to sell Novo’s Wegovy weight loss drug through a bundled offering on the telehealth company’s platform. Shares of Hims & Hers have fallen about 18% in pre-market trading following the news.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.